Previous close | 475.00 |
Open | 483.78 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 467.30 - 483.78 |
52-week range | 439.65 - 673.62 |
Volume | |
Avg. volume | 723 |
Market cap | 34.931B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 27.97 |
EPS (TTM) | 16.77 |
Earnings date | N/A |
Forward dividend & yield | 3.94 (0.83%) |
Ex-dividend date | 09 May 2023 |
1y target est | N/A |
Key Insights Lonza Group's estimated fair value is CHF410 based on 2 Stage Free Cash Flow to Equity Lonza Group is...
Lonza Group AG ( VTX:LONN ) missed earnings with its latest half-year results, disappointing overly-optimistic...
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.